Developer docs
API playgroundTry for free, no card

Search company profiles

Gelmetix

Full company profile

uuid0002uq7

Namestring
Gelmetix
Legal namestring
Gelmetix
Websiteurl
gelmetix.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Gelmetix is a UK-based medical device company founded in 2012 as a spin-out from the University of Manchester, developing injectable polymer hydrogel treatments for chronic lower-back pain caused by degenerative disc disease. Its lead product, DXM (Disc eXtra Matrix), is a pH-responsive, double cross-linked hydrogel designed to be injected into the nucleus pulposus to restore water content, rehydrate the disc, and maintain disc height, addressing the mechano-biological root cause of pain rather than masking symptoms. A second product, SXM, is in pre-clinical development and extends the same polymer platform to provide viscosity and lubrication for small joints, facet joints of the spine, and potentially larger joints.

The company's core technology is a patented polymer gel platform originating from over 25 years of academic research by co-founders Tony Freemont (Osteoarticular Pathology) and Brian Saunders (Polymer and Colloid Chemistry) at the University of Manchester, supported by peer-reviewed publications in materials science and clinical journals. DXM is positioned as a Class III medical device to be administered by discography-trained spine care specialists (spine surgeons, interventional radiologists, neurologists, rheumatologists) as a minimally invasive, ambulant procedure under local anesthetic, filling the treatment gap between conservative therapy and surgery.

Gelmetix is pre-revenue. Its near-term economics are driven by clinical advancement and capital raises rather than product sales; ~$14.75M has been disclosed across four funding rounds since 2014, with investors including Seneca Partners, The North West Fund, Fund Twenty8, Wealth Club, Spark Impact, and the University of Manchester. The future revenue model is expected to combine direct medical device sales to hospitals and specialty spine clinics with potential platform licensing for additional indications and for use as a carrier for regenerative agents such as anti-inflammatories or stem cells. The company is led by CEO Andy Weymann MD (former Smith+Nephew CMO) and maintains a board with deep orthopedic and medical device commercial experience.

Short descriptiontext

Gelmetix is a UK medical device company developing injectable pH-responsive hydrogel treatments, led by DXM for chronic lower-back pain from degenerative disc disease, with a follow-on SXM program for joint indications, sold to spine specialists once approved.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
disc rehydration therapy, hydrogel medical device, degenerative disc treatment, minimally invasive spine, polymer gel technology
Industry2 codes
PRIMARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Spinal Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Product Sales
TypeOne Time License
Description

Once DXM receives regulatory approval, the company plans to commercialize its hydrogel products for treating degenerative disc disease. As a Class III medical device requiring injection by trained physicians, the revenue model will likely involve direct sales to hospitals and specialty spine clinics, with potential for outpatient procedure-based billing.

gelmetix.com
2Platform Technology Licensing
TypeLicensing Royalties
Description

The patented polymer gel technology platform has potential for adaptation and extension for other uses including viscosity and lubrication for small joints, facet joints of the spine, and larger joints. The gels may also act as carriers for regenerative agents such as anti-inflammatories or stem cells, creating licensing opportunities.

gelmetix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gelmetix develops and intends to commercialize DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. The hydrogel restores nucleus pulposus water content and disc height, relieving chronic low-back pain through a minimally invasive, single-injection procedure performed by spine care physicians. A second pipeline product, SXM, is in pre-clinical development for joint lubrication and viscosity applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Sustained pain relief following single injection procedure
+3 more records
Product overview1 text field

Gelmetix is a medical technology company offering a patented polymer gel technology platform for treating chronic low-back pain and degenerative joint conditions. The company's primary product is DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel that provides disc rehydration therapy for degenerative disc disease. A second product, SXM, is in pre-clinical development. Both products leverage the company's core polymer gel technology platform, which can act as a carrier for regenerative agents and be adapted for multiple indications including small joints, facet joints, and larger joints throughout the body.

Product and service2 records
1DXM (Disc eXtra Matrix)
CategorySpinal Medical Device / Hydrogel Injectable
Description

A pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. It restores water content of the nucleus pulposus, re-establishes disc height and hydrostatic pressure, and provides sustained chronic low-back pain relief through a single minimally invasive procedure under local anaesthetic. Indicated for skeletally mature patients with confirmed degenerative disc disease and at least 3 months of prior non-operative treatment. Administered by trained interventional spine specialists (spine surgeons, interventional radiologists, neurologists, rheumatologists).

2SXM
CategoryJoint Lubrication / Viscosupplement Hydrogel (pipeline)
Description

A second hydrogel product built on Gelmetix's polymer gel platform, in pre-clinical development, designed to provide viscosity and lubrication to small joints, facet joints of the spine, and potentially larger joints throughout the body.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

University of Manchester spin-out founded in 2012. Technology originated from over 25 years of work by Tony Freemont (Professor of Osteoarticular Pathology) and Brian Saunders (Professor of Polymer and Colloid Chemistry). Prof. Tony Freemont serves as Co-Founder and Director.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

EIT Health Catapult program recognition in December 2020. Named 'one of the most promising biotech start-ups in Europe', providing validation and potential network benefits for the company.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops HYDRAFIL, an injectable hydrogel nucleus replacement for degenerative disc disease. Direct therapeutic and mechanistic analogue to Gelmetix's DXM, targeting the same patient population with a minimally invasive percutaneous injection.

TypeDirect peer
Description

Clinical-stage regenerative medicine company developing IDCT (injectable disc cell therapy) for degenerative disc disease. Targets the same lumbar indication as DXM via a percutaneous, image-guided procedure, competing for the same physician and patient pool.

TypeDirect peer
Description

Developing MPC-06-ID, an allogeneic mesenchymal stem cell therapy for chronic low-back pain due to degenerative disc disease. Closest large-cap public peer in the same indication, validating market demand and shaping the competitive landscape for DXM.

TypeEmerging player
Description

Clinical-stage company developing SB-01, an injectable therapeutic for chronic low-back pain associated with degenerative disc disease. Overlaps with DXM in mechanism (injectable, disease-modifying) and physician channel (interventional pain specialists).

TypeEmerging player
Description

Commercial-stage company focused on bone graft substitutes for spine surgery, including i-FACTOR Peptide Enhanced Bone Graft. Operates in adjacent spine biologics space with similar physician call points (spine surgeons) and biologics regulatory pathway.

TypeBroad incumbent
Description

Major spine hardware and enabling technology company (merged with NuVasive). Broad incumbent offering surgical solutions for degenerative disc disease; competes with DXM by anchoring the surgical treatment arm of the same care continuum.

TypeBroad incumbent
Description

Largest spine medtech player with broad portfolio of surgical, biologics, and pain stimulation solutions for degenerative disc disease. Sets the standard of care and reimbursement environment against which DXM will be evaluated.

TypeBroad incumbent
Description

Broad orthopedics and spine incumbent with disc replacement and surgical solutions for degenerative spine conditions. Comparable commercial reach and physician relationships in spine care that DXM will need to access or partner around.

TypeBroad incumbent
Description

Global medical device incumbent with significant orthopedics franchise. Relevant as Gelmetix CEO Andy Weymann MD is a former CMO of Smith+Nephew, and the company represents a potential strategic acquirer with established spine/orthopedic channels.

TypeBroad incumbent
Description

Spine and orthopedics company with motion preservation and biologic solutions for degenerative conditions. Comparable spine-focused medtech with overlapping physician call points and parallel regulatory/commercial pathway considerations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gelmetix

Spinal Medical Devicesgelmetix.com

Gelmetix is a UK medical device company developing injectable pH-responsive hydrogel treatments, led by DXM for chronic lower-back pain from degenerative disc disease, with a follow-on SXM program for joint indications, sold to spine specialists once approved.

What Gelmetix does

Gelmetix is a UK-based medical device company founded in 2012 as a spin-out from the University of Manchester, developing injectable polymer hydrogel treatments for chronic lower-back pain caused by degenerative disc disease. Its lead product, DXM (Disc eXtra Matrix), is a pH-responsive, double cross-linked hydrogel designed to be injected into the nucleus pulposus to restore water content, rehydrate the disc, and maintain disc height, addressing the mechano-biological root cause of pain rather than masking symptoms. A second product, SXM, is in pre-clinical development and extends the same polymer platform to provide viscosity and lubrication for small joints, facet joints of the spine, and potentially larger joints.

The company's core technology is a patented polymer gel platform originating from over 25 years of academic research by co-founders Tony Freemont (Osteoarticular Pathology) and Brian Saunders (Polymer and Colloid Chemistry) at the University of Manchester, supported by peer-reviewed publications in materials science and clinical journals. DXM is positioned as a Class III medical device to be administered by discography-trained spine care specialists (spine surgeons, interventional radiologists, neurologists, rheumatologists) as a minimally invasive, ambulant procedure under local anesthetic, filling the treatment gap between conservative therapy and surgery.

Gelmetix is pre-revenue. Its near-term economics are driven by clinical advancement and capital raises rather than product sales; ~$14.75M has been disclosed across four funding rounds since 2014, with investors including Seneca Partners, The North West Fund, Fund Twenty8, Wealth Club, Spark Impact, and the University of Manchester. The future revenue model is expected to combine direct medical device sales to hospitals and specialty spine clinics with potential platform licensing for additional indications and for use as a carrier for regenerative agents such as anti-inflammatories or stem cells. The company is led by CEO Andy Weymann MD (former Smith+Nephew CMO) and maintains a board with deep orthopedic and medical device commercial experience.

Gelmetix firmographics

Firmographics
Name
Gelmetix
Legal name
Gelmetix
Website
https://gelmetix.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Gelmetix is a UK medical device company developing injectable pH-responsive hydrogel treatments, led by DXM for chronic lower-back pain from degenerative disc disease, with a follow-on SXM program for joint indications, sold to spine specialists once approved.
Ownership category
akta.pro rank

Gelmetix industry classification

Industry
Product category
Spinal Medical Devices
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Disc rehydration therapy
  • Hydrogel medical device
  • Degenerative disc treatment
  • Minimally invasive spine
  • Polymer gel technology

Where Gelmetix is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Gelmetix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Product Sales: Once DXM receives regulatory approval, the company plans to commercialize its hydrogel products for treating degenerative disc disease. As a Class III medical device requiring injection by trained physicians, the revenue model will likely involve direct sales to hospitals and specialty spine clinics, with potential for outpatient procedure-based billing.
  2. Platform Technology Licensing: The patented polymer gel technology platform has potential for adaptation and extension for other uses including viscosity and lubrication for small joints, facet joints of the spine, and larger joints. The gels may also act as carriers for regenerative agents such as anti-inflammatories or stem cells, creating licensing opportunities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Gelmetix product offering

Product offering

Core offering

Gelmetix develops and intends to commercialize DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. The hydrogel restores nucleus pulposus water content and disc height, relieving chronic low-back pain through a minimally invasive, single-injection procedure performed by spine care physicians. A second pipeline product, SXM, is in pre-clinical development for joint lubrication and viscosity applications.

Product overview

Gelmetix is a medical technology company offering a patented polymer gel technology platform for treating chronic low-back pain and degenerative joint conditions. The company's primary product is DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel that provides disc rehydration therapy for degenerative disc disease. A second product, SXM, is in pre-clinical development. Both products leverage the company's core polymer gel technology platform, which can act as a carrier for regenerative agents and be adapted for multiple indications including small joints, facet joints, and larger joints throughout the body.

Differentiator

Problem solved

Functional benefit

Products and services

  • DXM (Disc eXtra Matrix) A pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. It restores water content of the nucleus pulposus, re-establishes disc height and hydrostatic pressure, and provides sustained chronic low-back pain relief through a single minimally invasive procedure under local anaesthetic. Indicated for skeletally mature patients with confirmed degenerative disc disease and at least 3 months of prior non-operative treatment. Administered by trained interventional spine specialists (spine surgeons, interventional radiologists, neurologists, rheumatologists).
  • SXM A second hydrogel product built on Gelmetix's polymer gel platform, in pre-clinical development, designed to provide viscosity and lubrication to small joints, facet joints of the spine, and potentially larger joints throughout the body.

Quantifiable outcome

  • Sustained pain relief following single injection procedure
  • +3 more outcomes

Companies that use Gelmetix

Customer profile

Segments2 records

Ideal customer profiles2 records

Gelmetix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Gelmetix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • University of ManchestercoreStrategic or Co-development Partner · 1 January 2012University of Manchester spin-out founded in 2012. Technology originated from over 25 years of work by Tony Freemont (Professor of Osteoarticular Pathology) and Brian Saunders (Professor of Polymer and Colloid Chemistry). Prof. Tony Freemont serves as Co-Founder and Director.
  • EIT HealthflagshipStrategic or Co-development PartnerEIT Health Catapult program recognition in December 2020. Named 'one of the most promising biotech start-ups in Europe', providing validation and potential network benefits for the company.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Gelmetix competitors and assessment

Company assessment

Direct peers

  • ReGelTec: Develops HYDRAFIL, an injectable hydrogel nucleus replacement for degenerative disc disease. Direct therapeutic and mechanistic analogue to Gelmetix's DXM, targeting the same patient population with a minimally invasive percutaneous injection.
  • DiscGenics: Clinical-stage regenerative medicine company developing IDCT (injectable disc cell therapy) for degenerative disc disease. Targets the same lumbar indication as DXM via a percutaneous, image-guided procedure, competing for the same physician and patient pool.
  • Mesoblast: Developing MPC-06-ID, an allogeneic mesenchymal stem cell therapy for chronic low-back pain due to degenerative disc disease. Closest large-cap public peer in the same indication, validating market demand and shaping the competitive landscape for DXM.

Emerging players

  • Spine BioPharma: Clinical-stage company developing SB-01, an injectable therapeutic for chronic low-back pain associated with degenerative disc disease. Overlaps with DXM in mechanism (injectable, disease-modifying) and physician channel (interventional pain specialists).
  • Cerapedics: Commercial-stage company focused on bone graft substitutes for spine surgery, including i-FACTOR Peptide Enhanced Bone Graft. Operates in adjacent spine biologics space with similar physician call points (spine surgeons) and biologics regulatory pathway.

Broad incumbents

  • Globus Medical: Major spine hardware and enabling technology company (merged with NuVasive). Broad incumbent offering surgical solutions for degenerative disc disease; competes with DXM by anchoring the surgical treatment arm of the same care continuum.
  • Medtronic (Spine & Biologics): Largest spine medtech player with broad portfolio of surgical, biologics, and pain stimulation solutions for degenerative disc disease. Sets the standard of care and reimbursement environment against which DXM will be evaluated.
  • Stryker (Spine): Broad orthopedics and spine incumbent with disc replacement and surgical solutions for degenerative spine conditions. Comparable commercial reach and physician relationships in spine care that DXM will need to access or partner around.
  • Smith+Nephew: Global medical device incumbent with significant orthopedics franchise. Relevant as Gelmetix CEO Andy Weymann MD is a former CMO of Smith+Nephew, and the company represents a potential strategic acquirer with established spine/orthopedic channels.
  • Orthofix Medical: Spine and orthopedics company with motion preservation and biologic solutions for degenerative conditions. Comparable spine-focused medtech with overlapping physician call points and parallel regulatory/commercial pathway considerations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Gelmetix social profiles

Digital presence

Gelmetix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gelmetix leadership team

Management profile

Number of profiles

Profiles10 records

Gelmetix funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gelmetix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gelmetix

What does Gelmetix do?

Gelmetix develops and intends to commercialize DXM (Disc eXtra Matrix), a pH-responsive, double cross-linked hydrogel injected under image guidance into degenerated lumbar intervertebral discs. The hydrogel restores nucleus pulposus water content and disc height, relieving chronic low-back pain through a minimally invasive, single-injection procedure performed by spine care physicians. A second pipeline product, SXM, is in pre-clinical development for joint lubrication and viscosity applications.

Is Gelmetix a public or private company?

Gelmetix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gelmetix founded?

Gelmetix was founded in 2012. It employs 1 to 10 people.

Where is Gelmetix based?

Gelmetix is headquartered in London, United Kingdom, in the Europe region.

How does Gelmetix make money?

Two revenue lines are on record. Medical Device Product Sales are the primary driver. The others are platform Technology Licensing.

Who are Gelmetix's main competitors?

Direct peers on record are ReGelTec, DiscGenics and Mesoblast. Emerging players are Spine BioPharma and Cerapedics. Broad incumbents are Globus Medical, Medtronic (Spine & Biologics), Stryker (Spine), Smith+Nephew and Orthofix Medical.

Does Gelmetix have an API?

No public API is recorded for Gelmetix.

What industry is Gelmetix in?

Gelmetix's product category is Spinal Medical Devices. Its primary akta.pro industry code is HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals